Development of an Automated Methodology for Calibration of Simplified Air-Side HVAC System Models and Estimation of Potential Savings from Retrofit/Commissioning Measures

This dissertation provides one methodology to determine potential energy savings of buildings with limited information. This methodology is based upon the simplified energy analysis procedure of HVAC systems and the control of the comfort conditions. Numerically, the algorithm is a tailored exhaustive search over all the independent variables that are commonly controlled for a specific type of HVAC system. The potential energy savings methodology has been applied in several buildings that have been retrofitted and/or commissioned previously. Results from the determined savings for the Zachry building at Texas A&M after being commissioned show a close agreement to the calculated potential energy savings (about 85%). Differences are mainly attributed to the use of simplified models. Due to the restriction of limited information about the building characteristics and operational control, the potential energy savings method requires the determination of parameters that characterize its thermal performance. Thus, a calibrated building is needed. A general procedure has been developed to carry out automated calibration of building energy use simulations. The methodology has been tested successfully on building simulations based on the simplified energy analysis procedure. The automated calibration is the minimization of the RMSE of the energy use over daily conditions. The minimization procedure is fulfilled with a non-canonical optimization algorithm, the Simulated Annealing, which mimics the Statistical Thermodynamic performance of the annealing process. That is to say, starting at a specified temperature the algorithm searches variable-space states that are steadier, while heuristically, by the Boltzmann distribution, the local minima is avoided. The process is repeated at a new lower temperature that is determined by a specific schedule until the global minimum is found. This methodology was applied to the most common air-handler units producing excellent results for ideal cases or for samples modified with a 1% white noise

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Study of Cubic Splines and Fourier Series as Interpolation Techniques for Filling in Short Periods of Missing Building Energy Use and Weather Data

Due to the character of the original source materials and the nature of batch digitization, quality control issues may be present in this document. Please report any quality issues you encounter to [email protected], referencing the URI of the item.Includes bibliographical references (leaves 84-87).Issued also on microfiche from Lange Micrographics.To define a single technique that can be reliably used for evaluation of missing data in time series of weather and building energy use data is a complex task. This thesis evaluates the application of spline and Fourier series mathematical techniques for filling in 1-6 hour periods of missing building energy use and weather data. The procedure followed created artificially missing points in measured data sets and was based on the local behavior of the data set around those pseudo-gaps. Seventeen approaches, five related to the spline technique and 12 belonging to the Fourier series, were tested over 20 yearlong samples of energy use and weather data. Two primary factors have been used to determine the preferred interpolation technique and approach to be used for filing data gaps. The principal factor is the reliability of the values yielded. The primary measure of reliability used was the mean bias error (MBE), although the Coefficient of Variation of the Root Mean Square (CV-RMSE) was also evaluated. The other factor is the simplicity of the interpolation technique. Simplicity is of great value when a technique must be applied to a large database where the data are managed and stored. The CV-RMSE is the more stable statistical parameter, produces values very similar for each of the techniques, and is independent of the number of points that are being evaluated. In contrast, the MBE is highly dependent on the number of gaps evaluated and shows a little more stability as the pseudo-gap increases. From the results of the normalized MBE, it is recommended that linear interpolation be used for tilling in missing data in time series of dry bulb and dew point temperature data. For building energy use data sets, the Fourier series approach with 24 data points before and after each gap and six constants was found to be the most suitable. In cases where there are not enough data points for the application of this approach, simple linear interpolation is recommended. Also linear interpolation gives the smallest relative errors of CV-RMSE when used to fill pseudo-gaps for all variables analyzed in this thesis

Energy Efficiency/Renewable Energy Impact in the Texas Emissions Reduction Plan (TERP), Volume III--Technical Appendix

The Energy Systems Laboratory (Laboratory), at the Texas Engineering Experiment Station of the Texas A&M University System, in fulfillment of its responsibilities under Texas Health and Safety Code Ann. § 388.003 (e), Vernon Supp. 2002, submits its seventh annual report, Energy Efficiency/Renewable Energy (EE/RE) Impact in the Texas Emissions Reduction Plan to the Texas Commission on Environmental Quality. The report is organized in three volumes: Volume I – Summary Report – provides an executive summary and overview; Volume II – Technical Report – provides a detailed report of activities, methodologies and findings; Volume III – Technical Appendix – contains detailed data from simulations for each of the counties included in the analysis

Iniciativas para el Desarrollo Agroalimentario y Agroindustrial del Istmo de Tehuantepec 2022 - No.6

Participantes: Ana Lilia Cruz Salinas, coordinadora general para el sector agroalimentario y agroindustrial. Guadalupe Martínez Calceros, moderadora. Lidia Alvarado de la Fuente, moderadora. Julio César Sandria Reynoso, rector de la Universidad Tecnológica del Suroeste de Veracruz. Alfredo Zamarripa Colmenero, coordinador de innovación e investigación. Luis Meneses Murillo, director general de la Comisión Nacional Forestal. Herminio Baltazar Cisneros, director general de las Universidades Tecnológicas y Politécnicas. Pedro Antonio Plateros Castelum, coordinador general de plantaciones forestales, comerciales de la Comisión Nacional Forestal. Enrique Carrasquilla Salas, ejecutivo principal de Ambiente y Cambio Climático en CAF. Hugo Raúl Paulín Hernández, subsecretario de Inclusión Productiva y Desarrollo Rural. Carlos Enrique González Vicente, Presidente de la Academia Nacional de Ciencias Forestales y Asociación Mexicana de Plantadores Forestales. Víctor Hugo Fernández Carrillo, director de Agropecuaria Santa Genoveva. Avelino Benigno Villa Salas, miembro de la Academia Nacional de Ciencias Forestales. Carlos Mallen Rivera, Investigador del Instituto Técnico Nacional de Investigaciones Forestales, Agrícolas y Pecuarias. Elías Ortiz Cervantes, Investigador del Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias. Saúl Monreal Rangel, Consultor Forestal. Enrique Espinosa Verduzco, CEO Ala BoOl. Juan Juárez Gómez, Coordinador General del Programa Sembrando Vida en Veracruz. César David Hernández Hernández, Profesor de la Universidad Tecnológica del Sureste de Veracruz.Tema: Cadenas forestales, limitaciones y potencialidades del hul